Current NIAID Biodefense Research Funding Opportunities
Preclinical Development
High-Priority Influenza Research Areas
Focus: Research aimed at developing tools to control epidemic influenza and the increasing threat of pandemic influenza is one of NIAID's highest priorities. Areas of high priority include, but are not limited to, the following:
- Development of improved drugs against influenza, including structure/function studies of influenza virus proteins with the goal of identifying new therapeutic targets.
- The development of novel influenza vaccines and vaccination strategies. Novel approaches might include developing and evaluating new vaccine formulations, adjuvants, immune response stimulators, protective T-cell and antibody epitopes, new routes of delivery, common epitope vaccines, and alternatives to egg-based vaccine production technologies.
- The development of sensitive, specific, and rapid clinical diagnostic tests for influenza.
- Evaluation of the immune response to infection and/or vaccination including cell-mediated and innate immunity.
- Determination of the molecular basis of virulence of influenza viruses in humans and animals.
- Evaluation of the molecular and/or environmental factors that influence the transmission of influenza viruses, including drug-resistant strains.
- Studies on the evolution and emergence of influenza viruses, including the identification of factors that affect influenza host-range and virulence.
- Virologic and serologic surveillance studies of the distribution of influenza viruses with pandemic potential in animal populations and in humans at the human/animal interface.
Standard Receipt Dates
The goal of this program announcement (PA) is to invite Small Business Innovation Research (SBIR) advanced technology projects that require a longer award period and greater award amount than those routinely allowed under the SBIR program, including
- Development of vaccines, biologics, drugs, and prevention strategies for infectious and immunologic diseases, allergy, and transplantation
- Development of vaccine, biologic, and drug delivery systems
- Development of assays and therapeutic monitoring systems for clinical and vaccine trials and for improved diagnosis of infectious, allergic, and immunologic diseases
Contact Info
Scientific/research issues: Gregory Milman
E-mail: gm16s@nih.gov
Financial/grants management matters: Pamela Fleming
E-mail: pf49e@nih.gov
This funding opportunity announcement (FOA) solicits Small Business Technology Transfer Research (STTR) grant applications from small business concerns (SBCs) for advanced technology projects that require a longer award period and greater award amount than those routinely allowed under the STTR program, including:
- A vaccine, biologic, or drug to treat an infectious disease, an immunologic disease, allergy, or transplantation.
- A vaccine, biologic or drug delivery system.
- Assays for the diagnosis of an infectious disease, immunologic disease, allergic disease, or as an aid to transplantation, or therapeutic monitoring systems for clinical trials of vaccines, biologics, drugs or transplantation.
Contact Info
Scientific/research issues: Gregory Milman
E-mail: gm16s@nih.gov
Financial/grants management matters: Pamela Fleming
E-mail: pf49e@nih.gov
back to top